#Octave bioscience full

All of this data is integrated into protocols, supported by decision support tools and feeds into a dashboard for ease of use. The third layer features real time tracking of symptoms via monitoring with mobile tools, sensors and wearables to identify changes in patient status and alert care teams. The second layer includes advanced measurement using improved MRI readings and interpretation to reveal more insights at the CNS layer, including the brain and spine. The first layer measures the patient’s underlying biology with blood-based biomarkers that quantitatively and objectively assess inflammation and immune modulation. It provides multiple layers of insight to provide a 360-degree view with a longitudinal perspective of disease progression. Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. In developing its care management platform, Octave Bioscience is integrating novel measurement tools with structured analytical data models, ensuring that the precision care solution for physicians and their patients is complementary to the corresponding care solution for pharmaceutical companies developing groundbreaking technologies, payers, and population health on a larger scale.įor more information, please visit and About the Octave Bioscience Comprehensive Care Platform This investment underscores industry interest in addressing the unmet needs of those living with, treating, and researching MS. “We look forward to working with the team as they continue to craft their platform focused on multi-modality, integrated findings and expanded disease insights.” Rubin, Ph.D., Managing Director of Merck GHIF. “Octave’s approach to improve patient outcomes in multiple sclerosis is powerful and we believe will have broader neurodegenerative disease applications,” said David M. We believe that this is just the beginning of a long and productive relationship that can help us shift the paradigm for patients with MS and a broad range of neurodegenerative diseases.”

#Octave bioscience full

“This investment further expands our already broad syndicate and further enables the full breadth of Octave’s services, ranging from measurement and management tools for physicians as they manage their patients to a precision-based set of tools and services that can help pharmaceutical companies better characterize their therapies and reveal additional insight to optimize their pipeline programs.

“The investment from Merck GHIF is a testament to the strength of our strategy, our team, technologies and platform,” said William Hagstrom, Chief Executive Officer and Founder of Octave. Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases. Octave to establish a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights for neurodegenerative diseases OCTAVE BIOSCIENCE ANNOUNCES STRATEGIC INVESTMENT FROM THE MERCK GLOBAL HEALTH INNOVATION FUND TO TRANSFORM DISEASE MEASUREMENT AND CARE FOR PATIENTS WITH NEURODEGENERATIVE DISEASES & KENILWORTH, N.J.-( BUSINESS WIRE)-Fifth paragraph of the release should read: For more information, please visit and (instead of For more information, please visit and The updated release reads: